Basic cancer research is essential for the success of personalised medicine

European Journal of Cancer

Volumn 49, Issue 12, 2013, Pages 2619-2620

  Yarden, Yosef ^a   Caldes, Carlos ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; IMATINIB; RITUXIMAB; TRASTUZUMAB;

ACHIEVEMENT; ARTICLE; BIOCHEMISTRY; CANCER RESEARCH; CANCER THERAPY; DNA REPAIR; INVESTMENT; NANOCHEMISTRY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SCIENTIST; TUMOR MICROENVIRONMENT;

CANCER;

ANIMALS; BIOMEDICAL RESEARCH; DRUG RESISTANCE, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; NEOPLASMS;

EID: 84879989552     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.04.020     Document Type: Article

References (0)